Aug 30, 2022 / 01:00PM GMT
Göran Forsberg - Cantargia AB - CEO
Thank you so much, and welcome to our half-year report. It's a real pleasure to present it. It's been a period which had a lot of excitement and lots of progress for Cantargia.
So if we go to slide number 2 and then to slide number 3. I'd just like to present myself. I'm Göran Forsberg, CEO of Cantargia, as we heard. And together with Bengt Jöndell, we will give the presentation.
So then if we go to slide number 4, this is, let's say, a summary of the most important news flow we had during this period. And by far, the most important part has been the presentation at ASCO in June, where we presented significant amount of new data for our lead asset, nadunolimab, both in pancreatic cancer and non-small cell lung cancer, here in combination with chemotherapy, as well as the first data set on nadunolimab in combination with Keytruda.
And we're really excited about what we have seen so far and how we can advance the development based on these data. And we will come back to that a little bit in more detail.
But before
Q2 2022 Cantargia AB Earnings Call Transcript
Aug 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers